Pharmaceutical Medicine

, Volume 29, Issue 5, pp 269–273 | Cite as

The European College of Neuropsychopharmacology (ECNP) Medicines Chest Initiative: Rationale and Promise

  • Ann Hayes
  • David Nutt
Leading Article


Development of drugs for treating diseases of the central nervous system (CNS) has had some of the highest attrition rates in the pharmaceutical industry, and the high risk and cost of development has led to many companies withdrawing from the area, despite significant unmet medical needs remaining and, hence, large commercial potential. For many CNS diseases, particularly psychiatric diseases, our understanding of the fundamental neuroscience associated with the disease is limited, which has led to a lack of predictivity of animal models and, therefore, often a failure of translation from animal models into human patients. Fortunately, technologies such as genetics and functional imaging are rapidly advancing our understanding of the human brain. Historically, many drugs used to treat CNS disorders were discovered by serendipity, when activity was noticed in the clinic during use for another indication. Such clinical ‘repurposing’ of drugs is still a highly useful strategy, but requires the availability of selective and potent tool compounds, with an accompanying regulatory data package, that will allow their use in people. Many such compounds exist within pharmaceutical companies but are sitting on the shelf because their development has been terminated. The Medicines Chest initiative was set up, funded by the European College of Neuropsychopharmacology (ECNP), in order to gain access to such compounds, so they could be used by academics and small companies in experimental medicine studies. The purpose of this article is to provide an update on progress with this initiative.


Neuropathic Pain Pregabalin Zolpidem Central Nervous System Disease Tiagabine 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



We would like to acknowledge the contribution of Dr. Gavin Kilpatrick in helping to set up the Medicines Chest.

Compliance with Ethical Standards


No funding was received for the publication of this article.

Conflict of interest

David Nutt has no conflicts of interest to report. Ann Hayes has received consulting fees and expenses from the European College of Neuropsychopharmacology (ECNP) for setting up the Medicines Chest.


  1. 1.
    Angelman Syndrome Foundation. Upcoming Angelman syndrome clinical trial. Accessed 13 Aug 2015.
  2. 2.
    Brown R, Basheer R, McKenna J, Strecker R, McCarley R. Control of sleep and wakefulness. Physiol Rev. 2012;92:1087–187.PubMedCentralCrossRefPubMedGoogle Scholar
  3. 3.
    Cheng YD, Al-Khoury L, Zivin JA. Neuroprotection for ischemic stroke: two decades of success and failure. NeuroRx. 2004;1:36–45.PubMedCentralCrossRefPubMedGoogle Scholar
  4. 4.
    Davie CA. A review of Parkinson’s disease. Br Med Bull. 2008;86:109–27.CrossRefPubMedGoogle Scholar
  5. 5.
    Eder D. CEE-03-310 CeNeS pharmaceuticals. Curr Opin Investig Drugs. 2002;3:284–8.PubMedGoogle Scholar
  6. 6.
    Enna SJ, Williams M. Challenges in the search for drugs to treat central nervous system disorders. J Pharmacol Exp Ther. 2009;329:404–11.CrossRefPubMedGoogle Scholar
  7. 7.
    Escudero I, Johnstone M. Genetics of schizophrenia. Curr Psychiatry Rep. 2014;16:502.CrossRefPubMedGoogle Scholar
  8. 8.
    ECNP. ECNP Medicines Chest. Accessed 13 Aug 2015.
  9. 9.
    Fletcher A, Forster E, Bill D, Brown G, Cliffe I, Hartley J, et al. Electrophysiological, biochemical, neurohormonal and behavioural studies with WAY-100635, a potent, selective and silent 5-HT1A receptor antagonist. Behav Brain Res. 1996;73:337–53.CrossRefPubMedGoogle Scholar
  10. 10.
    Giardina W, Williams M. Adrogolide HCl (ABT-431; DAS-431), a prodrug of the dopamine D1 receptor agonist, A-86929: preclinical pharmacology and clinical data. CNS Drug Rev. 2001;7:305–16.CrossRefPubMedGoogle Scholar
  11. 11.
    Gruber O, Chadha Santuccione A, Aach H. Magnetic resonance imaging in studying schizophrenia, negative symptoms, and the glutamate system. Front Psychiatry. 2014;5:32.PubMedCentralCrossRefPubMedGoogle Scholar
  12. 12.
    Halliday C, Jones B, Skingle M, Walsh D, Wise H, Tyers M. The pharmacology of fluparoxan: a selective alpha 2-adrenoceptor antagonist. Br J Pharmacol. 1991;102:887–95.PubMedCentralCrossRefPubMedGoogle Scholar
  13. 13.
    Lankford D, Corser B, Zheng Y, Li Z, Snavely D, Lines C, et al. Effect of gaboxadol on sleep in adult and elderly patients with primary insomnia: results from two randomized, placebo-controlled, 30-night polysomnography studies. Sleep. 2008;31:1359–70.PubMedCentralPubMedGoogle Scholar
  14. 14.
    Le Bon O, Lion K, Verbanck P, Kornreich C. Fluparoxan in male erectile disorder: a case report. J Psychopharmacol. 1995;9:67–8.CrossRefPubMedGoogle Scholar
  15. 15.
    McCulloch J. Excitatory amino acid antagonists and their potential for the treatment of ischaemic brain damage in man. Br J Clin Pharmacol. 1992;34:106–14.PubMedCentralCrossRefPubMedGoogle Scholar
  16. 16.
    Meera P, Wallner M, Otis TS. Molecular basis for the high THIP/gaboxadol sensitivity of extrasynaptic GABA(A) receptors. J Neurophysiol. 2011;106:2057–64.PubMedCentralCrossRefPubMedGoogle Scholar
  17. 17.
    Nutt D, Wilson S, Lingford-Hughes A, Myers J, Papadopoulos A, Muthukumaraswamy S. Differences between magnetoencephalographic (MEG) spectral profiles of drugs acting on GABA at synaptic and extrasynaptic sites: a study in healthy volunteers. Neuropharmacology. 2015;88:155–63.CrossRefPubMedGoogle Scholar
  18. 18.
    Olpe H, Karlsson G, Pozza M, Brugger F, Steinmann M, Van Riezen H, et al. CGP 35348: a centrally active blocker of GABAB receptors. Eur J Pharmacol. 1990;187:27–38.CrossRefPubMedGoogle Scholar
  19. 19.
    Raasch W. Central nervous system drug market. In: Wikinvest. Accessed 13 Aug 2015.
  20. 20.
    Seletti B, Benkelfat C, Blier P, Annable L, Gilbert F, de Montigny C. Serotonin1A receptor activation by flesinoxan in humans. Body temperature and neuroendocrine responses. Neuropsychopharmacology. 1995;13:93–104.CrossRefPubMedGoogle Scholar
  21. 21.
    Wafford K, Ebert B. Gaboxadol—a new awakening in sleep. Curr Opin Pharmacol. 2006;6:30–6.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2015

Authors and Affiliations

  1. 1.The Ann Hayes ConsultancyBuntingfordUK
  2. 2.Imperial CollegeLondonUK

Personalised recommendations